{"id":"al-794-suspension","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"AL-794 is formulated as a suspension for oral administration and is being developed as a treatment for respiratory syncytial virus infections. The precise mechanism by which it inhibits viral replication has not been publicly characterized in available literature.","oneSentence":"AL-794 is an antiviral compound designed to inhibit RSV replication, though its specific molecular target has not been publicly disclosed."},"_scrapedAt":"2026-03-28T05:51:56.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123501,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"ribavirin","brand":"Virazole","company":null,"rationale":"Established antiviral for RSV treatment"},{"name":"palivizumab","brand":"Synagis","company":"AstraZeneca","rationale":"Monoclonal antibody for RSV prophylaxis in high-risk infants"},{"name":"nirsevimab","brand":"Beyfortus","company":"Sanofi/AstraZeneca","rationale":"Long-acting monoclonal antibody for RSV prevention"}],"description":"AL-794 suspension is an investigational antiviral agent developed by Alios Biopharma Inc. for the treatment of respiratory syncytial virus (RSV) infections. The drug is currently in Phase 1 clinical development, with early studies evaluating its safety, tolerability, and pharmacokinetics in human subjects.","indications":{"approved":[{"status":"investigational","condition":"Respiratory Syncytial Virus (RSV) infection","patientPopulation":"Adult and potentially pediatric populations"}]},"trialDetails":[{"nctId":"NCT02588521","phase":"PHASE1","title":"A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2015-08-31","conditions":"Influenza","enrollment":152},{"nctId":"NCT02877160","phase":"PHASE1","title":"A Study to Assess the PK of AL-794 Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2016-06-30","conditions":"Influenza","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AL-794 suspension","genericName":"AL-794 suspension","companyName":"Alios Biopharma Inc.","companyId":"alios-biopharma-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}